comprehensive -WSS

comprehensive

author：comprehensive 2025-10-01 15:28:04 - browse：36155

European Medicines Agency Suffers Cyber Attack in Amsterdam — Paulo Amorim / VWPics via AP Images

LONDON — This week, European regulators are considering an appeal from Amylyx Pharmaceuticals after initially recommending against approving the company’s ALS treatment — the latest potential turning point for a drug that has seen its share of ups and downs with regulatory bodies.

In June, a European Medicines Agency committee issued a negative review of Amylyx’s drug, called Albrioza, and cast doubt on whether it had demonstrated effectiveness in its pivotal study. That would have almost certainly led to a rejection by regulators, but Amylyx requested what’s called a re-examination of the opinion. On Tuesday, the EMA held a meeting on the appeal, and a decision is expected in the coming weeks.

“There are patients who are dying and they really want access to the drug,” said Evy Reviers, the chairwoman of the European Organization for Professionals and Patients with ALS, whose father has the neurological disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Arena BioWorks launches in Cambridge to speed drug discovery

WSS

Study suggests Covid rebound is far more common with Paxlovid than without

Ventyx halts psoriasis drug development after lackluster trial results

Readout Newsletter: Zepbound, Valneva's vaccine, and more

Carbon Health diabetes program, a test of data

Experimental asthma app from Apple and Anthem shows promise

Medical school prerequisites are outdated

Wikipedia

comprehensive

leisure time

Drug repurposing or repositioning? The language matters

STAT Virtual Event: JPM Recap, Live!

Tori Bowie and the unacceptable rates of Black maternal death

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

New air purifier tech could be key to improving indoor air quality

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

FDA approval of Sarepta Duchenne genetic therapy gives me hope

JPM pitch from hospitals? Revenue streams outside of patient care

Alkermes shareholders re

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

knowledge

What is STAT's opinion section for?

Ohio still needs to do more to protect the right to abortion

Medicare’s new pay boost for primary care is angering specialists

Profiling embryos to choose those with higher IQs is almost a reality

Male doctors called my cancer incurable. A female doctor showed it wasn't

At JPM 2024, hospital systems pitch financial strength to investors

focus

hotspot

focus

entertainment